Multi-center experience of 164 consecutive Hemodialysis Reliable Outflow [HeRO] graft implants for hemodialysis treatment
S M Gage, H E Katzman, J R Ross, S E Hohmann, C A Sharpe, D W Butterly, J H Lawson, S M Gage, H E Katzman, J R Ross, S E Hohmann, C A Sharpe, D W Butterly, J H Lawson
Abstract
Objective: To report a multi-center experience with the novel Hemodialysis Reliable Outflow (HeRO) vascular access graft.
Materials and methods: Four centers conducted a retrospective review of end stage renal disease patients who received the HeRO device from implant to last available follow-up. Data is available on 164 patients with an accumulated 2092.1 HeRO implant months.
Results: At 6 months, HeRO primary and secondary patency is 60% and 90.8%, respectively and at 12 months, 48.8% and 90.8%, respectively. At 24 months, HeRO had a primary patency of 42.9% and secondary patency was 86.7%. Interventions to maintain or re-establish patency have been required in 71.3% of patients (117/164) resulting in an intervention rate of 1.5/year. Access related infections have been reported in 4.3% patients resulting in a rate of 0.14/1000 implant days.
Conclusions: In our experience the HeRO device has performed comparably to standard AVGs and has proven superior to TDCs in terms of patency, intervention, and infection rates when compared to the peer-reviewed literature. As an alternative to catheter dependence as a means for hemodialysis access, this graft could reduce the morbidity and mortality associated with TDCs and have a profound impact on the costs associated with catheter related infections and interventions.
Copyright © 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Source: PubMed